Form 483

Hikma Injectables USA Inc. Form 483, 2024-06-25

FDA issued a Form 483 to Hikma Injectables USA Inc. on 2024-06-25 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Hikma Injectables USA Inc. · Dayton, United States · Issued June 25, 2024

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

25 Jun 2024
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Edmund F Mrak, Ogechi C Nna, Luxuly Abraham

25 Jun 2024
21 CFR 211.160(b)(3)

Drug products - samples representative, identified properly

Cited by Edmund F Mrak, Ogechi C Nna, Luxuly Abraham

25 Jun 2024
21 CFR 211.42(c)(10)(iii)

Air Supply

Cited by Edmund F Mrak, Ogechi C Nna, Luxuly Abraham

25 Jun 2024
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Edmund F Mrak, Ogechi C Nna, Luxuly Abraham

Inspected site

HIHikma Injectables USA Inc.Dayton, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iii)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere